GeneDx Holdings Corp. (NASDAQ:WGS) Shares Sold by Baader Bank Aktiengesellschaft

Baader Bank Aktiengesellschaft cut its position in GeneDx Holdings Corp. (NASDAQ:WGS) by 33.0% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,700 shares of the company’s stock after selling 3,300 shares during the period. Baader Bank Aktiengesellschaft’s holdings in GeneDx were worth $515,000 at the end of the most recent quarter.

Other institutional investors have also recently modified their holdings of the company. American Century Companies Inc. raised its position in GeneDx by 36.1% during the 2nd quarter. American Century Companies Inc. now owns 17,258 shares of the company’s stock worth $451,000 after buying an additional 4,573 shares during the last quarter. Squarepoint Ops LLC raised its holdings in shares of GeneDx by 124.9% during the second quarter. Squarepoint Ops LLC now owns 59,949 shares of the company’s stock worth $1,567,000 after purchasing an additional 33,293 shares during the last quarter. Millennium Management LLC lifted its position in GeneDx by 193.5% during the second quarter. Millennium Management LLC now owns 311,401 shares of the company’s stock valued at $8,140,000 after purchasing an additional 205,318 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in GeneDx in the second quarter valued at $290,000. Finally, Algert Global LLC acquired a new stake in GeneDx during the 2nd quarter worth about $356,000. 61.72% of the stock is currently owned by hedge funds and other institutional investors.

GeneDx Trading Up 2.9 %

NASDAQ:WGS opened at $77.86 on Friday. The stock’s 50 day moving average price is $78.37 and its 200 day moving average price is $57.69. GeneDx Holdings Corp. has a 52-week low of $3.62 and a 52-week high of $98.87. The company has a quick ratio of 2.27, a current ratio of 2.40 and a debt-to-equity ratio of 0.25. The company has a market capitalization of $2.14 billion, a PE ratio of -25.04 and a beta of 2.02.

GeneDx (NASDAQ:WGS) last issued its earnings results on Tuesday, October 29th. The company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.25. The company had revenue of $76.90 million for the quarter, compared to analyst estimates of $64.98 million. GeneDx had a negative net margin of 31.25% and a negative return on equity of 13.35%. The firm’s revenue for the quarter was up 44.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.82) earnings per share. On average, research analysts anticipate that GeneDx Holdings Corp. will post -0.24 EPS for the current year.

Wall Street Analyst Weigh In

WGS has been the subject of a number of recent analyst reports. The Goldman Sachs Group lifted their price objective on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Craig Hallum raised their price objective on GeneDx from $70.00 to $95.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Wells Fargo & Company upped their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Finally, TD Cowen lifted their price target on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.67.

Insider Transactions at GeneDx

In other news, major shareholder School Of Medicine At Mo Icahn sold 126,782 shares of the company’s stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $70.78, for a total value of $8,973,629.96. Following the sale, the insider now owns 2,719,692 shares in the company, valued at approximately $192,499,799.76. This represents a 4.45 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Jason Ryan sold 31,510 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $71.28, for a total transaction of $2,246,032.80. Following the sale, the director now directly owns 15,490 shares of the company’s stock, valued at approximately $1,104,127.20. This represents a 67.04 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 361,737 shares of company stock worth $27,909,458 over the last quarter. 27.30% of the stock is currently owned by insiders.

About GeneDx

GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.